PMID- 1358654
OWN - NLM
STAT- MEDLINE
DCOM- 19921222
LR  - 20190623
IS  - 0014-2999 (Print)
IS  - 0014-2999 (Linking)
VI  - 221
IP  - 2-3
DP  - 1992 Oct 20
TI  - Long-term alteration in the central monoaminergic systems of the rat by 
      2,4,5-trihydroxyamphetamine but not by 
      2-hydroxy-4,5-methylenedioxymethamphetamine or 
      2-hydroxy-4,5-methylenedioxyamphetamine.
PG  - 281-8
AB  - The long-term effects of three metabolites of 3,4-methylenedioxymethamphetamine 
      (MDMA) on the central monoaminergic systems of the rat were examined. Seven days 
      after the intracerebroventricular administration of 0.25 and 0.5 mumol 
      2,4,5-trihydroxyamphetamine, hippocampal tryptophan hydroxylase (TPH) activity 
      was reduced to 5 and 1% of control, respectively, while norepinephrine (NE) 
      concentration was depressed to 10 and 18% of control. These two respective 
      dosages also decreased striatal tyrosine hydroxylase (TH) activity to 67 and 10% 
      of control, respectively, while nigral TH activity was reduced to 59 and 20% of 
      control. Striatal TPH activity was reduced to 74 and 81% of control, 
      respectively, while the activity in the dorsal and median raphe remained 
      unaltered. The intracerebroventricular administration of 1 mumol 
      2-hydroxy-4,5-methylenedioxymethamphetamine (6-OH-MDMA) failed to alter TPH 
      activity, TH activity or NE concentration after 14 days. In contrast, 1 mumol of 
      2-hydroxy-4,5-methylenedioxyamphetamine (6-OH-MDA) induced a 30% increase in 
      striatal TPH activity and a 50% increase in nigral TH activity. The study of the 
      formation of 2,4,5-trihydroxyamphetamine after MDMA treatment may provide insight 
      as to how MDMA destroys serotonergic nerve terminals.
FAU - Elayan, I
AU  - Elayan I
AD  - Department of Pharmacology and Toxicology, University of Utah, Salt Lake City 
      84112.
FAU - Gibb, J W
AU  - Gibb JW
FAU - Hanson, G R
AU  - Hanson GR
FAU - Foltz, R L
AU  - Foltz RL
FAU - Lim, H K
AU  - Lim HK
FAU - Johnson, M
AU  - Johnson M
LA  - eng
GR  - DA 00869/DA/NIDA NIH HHS/United States
GR  - DA 04222/DA/NIDA NIH HHS/United States
GR  - DA 05860/DA/NIDA NIH HHS/United States
PT  - Journal Article
PT  - Research Support, U.S. Gov't, P.H.S.
PL  - Netherlands
TA  - Eur J Pharmacol
JT  - European journal of pharmacology
JID - 1254354
RN  - 0 (Amphetamines)
RN  - 136706-33-7 (2,4,5-trihydroxyamphetamine)
RN  - 136706-34-8 (6-hydroxy-N-methyl-3,4-methylenedioxyamphetamine)
RN  - 145284-65-7 (2-hydroxy-4,5-methylenedioxyamphetamine)
RN  - 333DO1RDJY (Serotonin)
RN  - 4764-17-4 (3,4-Methylenedioxyamphetamine)
RN  - EC 1.14.16.2 (Tyrosine 3-Monooxygenase)
RN  - EC 1.14.16.4 (Tryptophan Hydroxylase)
RN  - KE1SEN21RM (N-Methyl-3,4-methylenedioxyamphetamine)
RN  - VTD58H1Z2X (Dopamine)
RN  - X4W3ENH1CV (Norepinephrine)
SB  - IM
MH  - 3,4-Methylenedioxyamphetamine/*analogs & derivatives/metabolism/toxicity
MH  - Amphetamines/toxicity
MH  - Animals
MH  - Brain/*drug effects/metabolism
MH  - Dopamine/*metabolism
MH  - Male
MH  - N-Methyl-3,4-methylenedioxyamphetamine
MH  - Norepinephrine/*metabolism
MH  - Rats
MH  - Rats, Sprague-Dawley
MH  - Serotonin/*metabolism
MH  - Tryptophan Hydroxylase/analysis
MH  - Tyrosine 3-Monooxygenase/analysis
EDAT- 1992/10/20 00:00
MHDA- 1992/10/20 00:01
CRDT- 1992/10/20 00:00
PHST- 1992/10/20 00:00 [pubmed]
PHST- 1992/10/20 00:01 [medline]
PHST- 1992/10/20 00:00 [entrez]
AID - 0014-2999(92)90714-F [pii]
AID - 10.1016/0014-2999(92)90714-f [doi]
PST - ppublish
SO  - Eur J Pharmacol. 1992 Oct 20;221(2-3):281-8. doi: 10.1016/0014-2999(92)90714-f.